Bernard "Chip" Cole got the call in late December. The U.S. Food and Drug Administration summoned the University of Vermont biostatistician for another mission. Since 2013, Cole has sat on an important FDA ...
In a deal that would combine two generic drugmakers that recently left the U.S. for Europe, Mylan says it wants to buy Perrigo for $205 per share, or $28.86 billion.
The U.S. Food and Drug Administration must hold companies to a higher standard when it comes to herbal supplements, said Edward Bednarczyk, University at Buffalo pharmacy practice chair, PharmD.
Bristol-Myers Squibb, one of the world's largest drugmakers, will team up with a Dutch biotechnology company whose first approved drug could cost more than $1 million.
Bubbles invisible to the naked eye could provide the next breakthrough in treating heart and eye problems – and present an alternate treatment for cancer and cellulite as well.
The global pharmaceutical industry is pouring billions of dollars into developing treatments for rare diseases, which once drew little interest from major drugmakers but now point the way toward a new era ...
Gilead Sciences said multiple Canadian provinces will provide access to the biotechnology company's hepatitis C drug Harvoni following a positive reimbursement recommendation from regulators.
A generic version of insulin, the lifesaving diabetes drug used by 6 million people in the United States, has never been available in this country because drug companies have made incremental improvements ...
Google-backed genetic testing company 23andMe is launching its own drug development unit, betting that it can translate its database of customer DNA information into novel medicines.
With patients facing greater exposure to the high cost of new medications, President Barack Obama on Monday called for government to use its buying power to squeeze drug companies for lower prices.
Sun Pharmaceuticals will sell the rights to one generic drug as part of its purchase of competitor Ranbaxy Laboratories, U.S. antitrust regulators said Friday.
An examination of the potential interaction between pharmaceutical companies and the U.S. Food and Drug Administration (FDA) to discuss future studies finds that one-quarter of recent new drug approvals occurred without any ...
The Cystic Fibrosis Foundation says it has sold royalty rights worth $3.3 billion for innovative drugs it helped develop with Vertex Pharmaceuticals Incorporated.
You can't catch attention deficit hyperactivity disorder (ADHD). Yet the diagnosis and treatment of this behavioral condition is spreading like a contagion—surging as much as tenfold in some countries.
As the Ebola crisis in Africa continues and concern ramps up in the United States, a pharmaceutical company with a Corvallis connection is ready to respond with a limited amount of a potentially promising new drug.